LeMaitre Vascular Inc. (LMAT) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

LeMaitre Vascular Inc. (NASDAQ:LMAT) posted its quarterly earnings data on Wednesday. The company reported $0.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.03.

In related news, CEO George W. Lemaitre sold 110,189 shares of the firm’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $16.17, for a total value of $1,781,756.13. Following the completion of the sale, the chief executive officer now owns 3,549,133 shares in the company, valued at $57,389,480.61. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 1,740 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $15.49, for a total transaction of $26,952.60. Following the completion of the sale, the chief executive officer now owns 3,522,749 shares of the company’s stock, valued at approximately $54,567,382.01. The disclosure for this sale can be found here.

LeMaitre Vascular (NASDAQ:LMAT) traded up 1.53% on Wednesday, reaching $14.63. The company had a trading volume of 61,283 shares. The stock has a 50 day moving average price of $14.29 and a 200 day moving average price of $14.69. The stock has a market capitalization of $268.88 million and a PE ratio of 32.58. LeMaitre Vascular has a 52-week low of $11.75 and a 52-week high of $18.44.

LMAT has been the subject of several research reports. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th. Canaccord Genuity reiterated a “buy” rating and set a $18.00 price objective (up from $6.00) on shares of LeMaitre Vascular in a research note on Tuesday, May 3rd. Roth Capital boosted their price objective on LeMaitre Vascular from $18.00 to $18.50 and gave the stock a “buy” rating in a research note on Tuesday, May 3rd. Finally, Brean Capital reiterated a “buy” rating on shares of LeMaitre Vascular in a research note on Tuesday, May 3rd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.61.

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.